hy-p1080a Search Results


ω agatoxin iva tfa  (MedChemExpress)
93
MedChemExpress ω agatoxin iva tfa
FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel <t>antagonist</t> <t>ω-agatoxin</t> <t>IVA</t> on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.
ω Agatoxin Iva Tfa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-p1080a/%CF%89-Agatoxin+IVA/pm40361281-147-35-50
Average 93 stars, based on 1 article reviews
ω agatoxin iva tfa - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel antagonist ω-agatoxin IVA on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.

Journal: British journal of pharmacology

Article Title: Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance.

doi: 10.1111/bph.70048

Figure Lengend Snippet: FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel antagonist ω-agatoxin IVA on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.

Article Snippet: ATP (Cat. No. HY-B2176), retinoic acid (RA, Cat. No. HY-14649), acadesine (Cat. No. HY-13417), dorsomorphin (Cat. No. HY-13418A), coenzyme Q10 (Cat. No. HY-N0111), paclitaxel (Cat. No. HY-B0015), (-)-(S)-BayK8644 (Cat. No. HY-15124), GV-58 (Cat. No. HY-12498), ω-agatoxin IVA TFA (Cat. No. HY-P1080A) and ziconotide acetate (Cat. No. HY-P0062B) were purchased from MedChemExpress (Shanghai, China).

Techniques: Inhibition, Saline, Comparison